Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

Urology

Volumn 59, Issue 5, 2002, Pages 652-656

  Stephenson, Andrew J ^a   Aprikian, Armen G ^a   Souhami, Luis ^a   Behlouli, Hassan ^a   Jacobson, Avrum I ^a   Bégin, Louis R ^a   Tanguay, Simon ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA;

BIOPSY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0036247796     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01526-1     Document Type: Article

References (21)

1. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening
2. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
3. Distinguishing clinically important from unimportant prostate cancers before treatment: Value systematic biopsies
4. Results of conservative management of clinically localized prostate cancer
5. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate
6. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
7. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
8. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
9. Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
10. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
11. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer
12. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma
13. Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior
14. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: Defining a 'rapid riser' subset
15. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma
16. Correlation between Gleason score and radical prostatectomy specimen: Accuracy and clinical implications
17. Pretreatment prostate specific antigen doubling times: Use in patients before radical prostatectomy
18. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer
19. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy
20. Clinical significance of repeat sextant biopsies in prostate cancer patients
21. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer